Search results - 3 results
Annual Report Belgian Cystic Fibrosis Registry 2018
period at about 3.5% over the years since 2014. Thanks to improved disease management and novel treatments, the life expectancy and the quality of life of patients with CF has improved significantly when ...
Annual Report Belgian Cystic Fibrosis Registry 2017
levels above 10.0% since 2012, but reaching 11.4% in 2017. The prevalence of the Burkholderia cepacia complex on the other hand has decreased to 2.9%, after a stable period at 3.5% over the years since ...
Risk factors and impact of allergic bronchopulmonary aspergillosis in Pseudomonas aeruginosa-negative CF patients.
the index year. During the period preceding the index year, significantly more ABPA patients were treated with rhDNase and inhaled corticosteroids. CONCLUSIONS: Bronchial damage cannot be considered as ...